Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

227.87
+0.56000.25%
Post-market: 227.870.00000.00%19:30 EDT
Volume:641.44K
Turnover:145.77M
Market Cap:15.08B
PE:17.36
High:229.02
Open:227.63
Low:225.20
Close:227.31
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:0.88
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):13.12
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.33
PE(LYR):-51.58

Loading ...

BioMarin Signs Global Patent License Deal with Ascendis for TransCon CNP Products

Reuters
·
Oct 01

Barclays Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Sep 30

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Lakefront Biotherapeutics (LKFT) and 10x Genomics (TXG)

TIPRANKS
·
Sep 28

Ascendis Pharma Price Target Maintained with a $300.00/Share by Cantor Fitzgerald

Dow Jones
·
Sep 28

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ascendis Pharma (ASND) and Charles River Labs (CRL)

TIPRANKS
·
Sep 16

Ascendis Pharma A/S Stock (ASND) Moved Down by 12.08% on Sep 15: What Signal Does It Send?

TradingKey
·
Sep 16

Movement Alert|Ascendis Pharma A/S Falls 12.23% in Regular Trading, Termination of Novo Nordisk Obesity Drug Collaboration Triggers Selloff

Market Focus
·
Sep 16

Ascendis Pharma Tumbles on Novo Nordisk Collab Termination

Reuters
·
Sep 15

Ascendis Pharma falls -12.1%

TIPRANKS
·
Sep 15

Sector Update: Healthcare

MT Newswires Live
·
Sep 15

Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved

Dow Jones
·
Sep 15

Ascendis Pharma to regain rights to TransCon technology-based products

TIPRANKS
·
Sep 15

Ascendis Pharma announces $400M share repurchase plan

TIPRANKS
·
Sep 15

Ascendis Pharma a/S - to Regain Exclusive Rights to Transcon Technology in Metabolic and Cardiovascular Diseases

THOMSON REUTERS
·
Sep 15

Press Release: Ascendis Announces Planned $400 Million Share Repurchase Program

Dow Jones
·
Sep 15

Ascendis Pharma SVP & PAO Mads Bodenhoff Disposes of 3,000 Common Shares Worth $810,570

Reuters
·
Sep 10

Ascendis Pharma announces data from reACHin Trial

TIPRANKS
·
Sep 10

Ascendis Pharma Director Lars Holtug Disposes of 236 Shares Worth $62,337.59

Reuters
·
Sep 04

Ascendis Pharma is Maintained at Outperform by Oppenheimer

Dow Jones
·
Sep 03

Ascendis Pharma a/S : Oppenheimer Raises Target Price to $312 from $304

THOMSON REUTERS
·
Sep 02